/주식/LXEO
LXEO

LXEO

USD

Lexeo Therapeutics Inc. Common Stock

$8.190-0.110 (-1.325%)

실시간 가격

Healthcare
생명공학
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$8.300

고가

$8.355

저가

$7.660

거래량

2.85M

기업 기본 정보

시가총액

597.8M

산업

생명공학

국가

United States

거래 통계

평균 거래량

1.04M

거래소

NGM

통화

USD

52주 범위

저가 $1.45현재가 $8.190고가 $11.72

관련 뉴스

PR Newswire

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Equity InsiderNews Commentary – Conventional small molecule approaches have struggled to address genetic defects and complex disease mechanisms,...

더 보기
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $13

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Lexeo Therapeutics with a Buy and lowers the price target from $15 to $13.

더 보기
HC Wainwright & Co. Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $13
Analyst Upgrades

Chardan Capital Maintains Buy on Lexeo Therapeutics, Raises Price Target to $17

Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics with a Buy and raises the price target from $15 to $17.

더 보기
Chardan Capital Maintains Buy on Lexeo Therapeutics, Raises Price Target to $17
GlobeNewswire

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

U.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to support a Biologics License Application (BLA) for Accelerated Approval Interim clinical data

더 보기
Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy